PSYENCE BIOMEDICAL LTD. (PBM) Form 20-F — Jun 22, 2026
Psyence Biomedical reported a net loss of $6.89 million for the fiscal year ended March 31, 2026, with no revenue generated and no products approved for commercial sale. The company ended the period with approximately $7.5 million in cash and restricted cash, expecting existing funds to be sufficient for more than 12 months but acknowledging the need for substantial additional capital to fund ongoing clinical trials and operations. The filing disclosed multiple reverse stock splits executed in 2024, 2025, and 2026 to regain compliance with Nasdaq's minimum bid price requirement, highlighting ongoing volatility and financial distress risks.
Key figures
- Net Income
- $6.89 million loss
- Cash Position
- $7,491,954
- Shares Outstanding
- 2293277
- Rd Rebate2023
- AUD $1,336,622
- Rd Rebate2025
- AUD $441,732
- Warrants Exercisable
- 45112
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.